MDR-TB
9
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
44%
4 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)
A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes
Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)
Triage Test for All Oral DR-TB Regimen (TRiAD Study)
A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB
HIV and Multi-Drug Resistant Tuberculosis: a Study on Clinical Outcomes
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
Saliva and Dried Blood Spot Therapeutic Drug Monitoring for MDR-TB in Tanzania